Tildrakizumab in Complex Psoriatic Patients: An Experience in Emilia-Romagna (Italy). Issue 2 (March 2023)

• Record Type: Journal Article
• Authors: Bardazzi, Federico; Viviani, Filippo; Piraccini, Bianca Maria; Lasagni, Claudia; Bigi, Laura; Manfredini, Marco; Pongetti, Linda; Di Lernia, Vito; Corazza, Monica; Pepe, Francesca
• Is Part Of: Journal of cutaneous medicine and surgery. Volume 27:Issue 2(2023)
• Page Start: 126
• Page End: 132
• Publication Date: 2023-03
• Subjects: psoriasis -- tildrakizumab -- comorbidities -- elderly patients -- difficult-to-treat areas; Dermatology -- Periodicals; Skin -- Diseases -- Treatment -- Periodicals; Skin -- Surgery -- Periodicals; Dermatology -- Canada -- Periodicals; Skin -- Diseases -- Treatment -- Canada -- Periodicals; Skin -- Surgery -- Canada -- Periodicals; 616.5005
• DOI: 10.1177/12034754231155889
• Languages: English
• ISSNs: 1203-4754

Abstract

Background: IL-23 inhibitors are the latest class of biologic drugs approved for moderate-to-severe psoriasis. Objectives: to investigate real-life safety and efficacy of tildrakizumab. Methods: demographic data, medical history, psoriasis disease history, PASI, DLQI, BSA, NAPSI were recorded at weeks 0, 12, 24, 36. Results: PASI, BSA, DLQI and NAPSI all decreased rapidly during the 36 week follow-up period. PASI score reduced from 12.28 to 4.65 by week 12, followed by a further decrease to 1.18 at week 36 Multiple logistic regression showed that smoking, BMI ≥30, ≥3 comorbidities, previous systemic traditional or biologic drugs, psoriatic arthritis nor difficult-to-treat areas influenced the reduction of PASI and NAPSI scores during treatment with tildrakizumab ( P > .05). Conclusions: we assessed a good performance of tildrakizumab in patients with multiple comorbidities, multi-failure, elderly patients, and in subjects with psoriatic arthritis.